newsfilter
← Latest News
GlobeNewswire·

Small Pharma Reports Fiscal Third Quarter 2023 Highlights

Positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced in the first in-human study of SPL028 LONDON, Jan. 25, 2023 (GLOBE